Carrie Marshall
Concepts (103)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Biopsy, Fine-Needle | 3 | 2019 | 71 | 0.470 |
Why?
| Pathology, Molecular | 1 | 2012 | 26 | 0.430 |
Why?
| Mediastinum | 1 | 2011 | 21 | 0.400 |
Why?
| Lymphoproliferative Disorders | 1 | 2011 | 46 | 0.380 |
Why?
| Lymph Nodes | 1 | 2011 | 466 | 0.320 |
Why?
| Thyroid Nodule | 2 | 2019 | 38 | 0.310 |
Why?
| Thyroid Neoplasms | 2 | 2019 | 277 | 0.250 |
Why?
| Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 967 | 0.240 |
Why?
| Carcinoma | 2 | 2017 | 212 | 0.240 |
Why?
| Biomarkers, Tumor | 2 | 2021 | 1076 | 0.230 |
Why?
| Gene Expression Regulation, Neoplastic | 2 | 2021 | 1183 | 0.230 |
Why?
| Paraneoplastic Syndromes | 1 | 2021 | 14 | 0.210 |
Why?
| Motor Neuron Disease | 1 | 2021 | 17 | 0.210 |
Why?
| Bronchoscopy | 2 | 2016 | 254 | 0.210 |
Why?
| Laboratories | 2 | 2019 | 106 | 0.200 |
Why?
| Diagnosis, Differential | 4 | 2017 | 1423 | 0.190 |
Why?
| Pheochromocytoma | 1 | 2021 | 54 | 0.190 |
Why?
| Paraganglioma | 1 | 2021 | 48 | 0.190 |
Why?
| Neuroendocrine Tumors | 1 | 2021 | 91 | 0.180 |
Why?
| Hodgkin Disease | 1 | 2021 | 121 | 0.180 |
Why?
| Carcinoma, Papillary | 3 | 2017 | 78 | 0.180 |
Why?
| Lung Neoplasms | 1 | 2012 | 2216 | 0.180 |
Why?
| Pathology | 1 | 2019 | 21 | 0.180 |
Why?
| Oncogene Proteins, Fusion | 1 | 2021 | 182 | 0.170 |
Why?
| Pathology, Clinical | 2 | 2017 | 34 | 0.170 |
Why?
| Trans-Activators | 1 | 2021 | 382 | 0.160 |
Why?
| Histocytochemistry | 1 | 2017 | 84 | 0.150 |
Why?
| Adenocarcinoma, Follicular | 1 | 2017 | 34 | 0.150 |
Why?
| Transcriptome | 2 | 2021 | 774 | 0.150 |
Why?
| Cytodiagnosis | 1 | 2016 | 29 | 0.140 |
Why?
| Image-Guided Biopsy | 1 | 2016 | 34 | 0.140 |
Why?
| Optic Nerve | 1 | 2016 | 66 | 0.140 |
Why?
| Precision Medicine | 1 | 2019 | 371 | 0.130 |
Why?
| Reproducibility of Results | 4 | 2019 | 2977 | 0.130 |
Why?
| Ultrasonography, Interventional | 1 | 2016 | 156 | 0.120 |
Why?
| Alphapapillomavirus | 1 | 2014 | 38 | 0.120 |
Why?
| Endosonography | 2 | 2016 | 148 | 0.120 |
Why?
| Neoplasms | 2 | 2019 | 2235 | 0.120 |
Why?
| Spinal Cord | 1 | 2016 | 364 | 0.110 |
Why?
| Glioblastoma | 1 | 2016 | 262 | 0.110 |
Why?
| ErbB Receptors | 2 | 2016 | 571 | 0.110 |
Why?
| Gene Expression Profiling | 1 | 2019 | 1625 | 0.100 |
Why?
| CD5 Antigens | 1 | 2011 | 10 | 0.100 |
Why?
| Immunoglobulin kappa-Chains | 1 | 2011 | 21 | 0.100 |
Why?
| ADP-ribosyl Cyclase 1 | 1 | 2011 | 36 | 0.100 |
Why?
| Receptors, IgE | 1 | 2011 | 47 | 0.100 |
Why?
| CD3 Complex | 1 | 2011 | 99 | 0.100 |
Why?
| Papillomavirus Infections | 1 | 2014 | 267 | 0.100 |
Why?
| Immunophenotyping | 1 | 2011 | 288 | 0.090 |
Why?
| Lung Diseases | 1 | 2016 | 764 | 0.080 |
Why?
| Aged, 80 and over | 3 | 2019 | 6845 | 0.080 |
Why?
| Flow Cytometry | 1 | 2011 | 1128 | 0.080 |
Why?
| Mutation | 2 | 2021 | 3493 | 0.070 |
Why?
| Kidney Diseases, Cystic | 1 | 2006 | 20 | 0.070 |
Why?
| Aged | 5 | 2021 | 20495 | 0.070 |
Why?
| Sensitivity and Specificity | 1 | 2011 | 1855 | 0.070 |
Why?
| Humans | 12 | 2021 | 122796 | 0.060 |
Why?
| Middle Aged | 5 | 2019 | 28563 | 0.050 |
Why?
| Lung Diseases, Interstitial | 1 | 2006 | 465 | 0.050 |
Why?
| Fatal Outcome | 1 | 2021 | 299 | 0.050 |
Why?
| Adult | 5 | 2019 | 32385 | 0.050 |
Why?
| United States | 4 | 2019 | 13272 | 0.050 |
Why?
| Adrenal Gland Neoplasms | 1 | 2021 | 82 | 0.050 |
Why?
| Female | 7 | 2021 | 63629 | 0.050 |
Why?
| Pre-Analytical Phase | 1 | 2019 | 1 | 0.050 |
Why?
| Wnt Signaling Pathway | 1 | 2021 | 153 | 0.040 |
Why?
| Singapore | 1 | 2019 | 15 | 0.040 |
Why?
| Tumor Cells, Cultured | 1 | 2021 | 904 | 0.040 |
Why?
| Accreditation | 1 | 2019 | 96 | 0.040 |
Why?
| Thyroid Gland | 1 | 2017 | 86 | 0.040 |
Why?
| X-linked Nuclear Protein | 1 | 2016 | 7 | 0.040 |
Why?
| Neoplasm Grading | 1 | 2017 | 265 | 0.030 |
Why?
| Observer Variation | 1 | 2017 | 314 | 0.030 |
Why?
| Breast Neoplasms | 1 | 2007 | 1994 | 0.030 |
Why?
| Societies, Medical | 1 | 2019 | 741 | 0.030 |
Why?
| PTEN Phosphohydrolase | 1 | 2016 | 149 | 0.030 |
Why?
| DNA Helicases | 1 | 2016 | 136 | 0.030 |
Why?
| Vaginal Smears | 1 | 2014 | 48 | 0.030 |
Why?
| Papanicolaou Test | 1 | 2014 | 40 | 0.030 |
Why?
| Predictive Value of Tests | 1 | 2019 | 1947 | 0.030 |
Why?
| Cell Proliferation | 1 | 2021 | 2328 | 0.030 |
Why?
| Neoplasm Staging | 1 | 2017 | 1234 | 0.030 |
Why?
| Male | 3 | 2019 | 59639 | 0.030 |
Why?
| Biomedical Research | 1 | 2019 | 630 | 0.030 |
Why?
| Apoptosis | 1 | 2021 | 2532 | 0.030 |
Why?
| Uterine Cervical Neoplasms | 1 | 2014 | 215 | 0.020 |
Why?
| Nuclear Proteins | 1 | 2016 | 618 | 0.020 |
Why?
| Risk | 1 | 2014 | 890 | 0.020 |
Why?
| Histones | 1 | 2016 | 562 | 0.020 |
Why?
| Membrane Proteins | 1 | 2016 | 1093 | 0.020 |
Why?
| Adolescent | 2 | 2019 | 18948 | 0.020 |
Why?
| Mastectomy, Modified Radical | 1 | 2007 | 7 | 0.020 |
Why?
| Selective Estrogen Receptor Modulators | 1 | 2007 | 26 | 0.020 |
Why?
| Prospective Studies | 1 | 2019 | 6704 | 0.020 |
Why?
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2007 | 57 | 0.020 |
Why?
| Radiotherapy, Adjuvant | 1 | 2007 | 191 | 0.020 |
Why?
| Tamoxifen | 1 | 2007 | 198 | 0.020 |
Why?
| Magnetic Resonance Imaging | 1 | 2016 | 3264 | 0.020 |
Why?
| Surveys and Questionnaires | 1 | 2016 | 4882 | 0.010 |
Why?
| Young Adult | 1 | 2019 | 11094 | 0.010 |
Why?
| Lung | 1 | 2016 | 3830 | 0.010 |
Why?
| Retrospective Studies | 1 | 2014 | 13433 | 0.010 |
Why?
| Child | 1 | 2016 | 19561 | 0.010 |
Why?
|
|
Marshall's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|